DERM at a glance
Journey Medical Corp (DERM, SEC CIK 1867066) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on August 12, 2026, an 8-K current report on August 12, 2026 and Form 4 insider filings as recently as June 29, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Journey Medical Corp (DERM) reported revenue of $61.2 million (up 11.1% from FY2024) and a net loss of $11.4 million. Diluted EPS was -$0.47.
- As of June 30, 2026, 16 institutional investment managers tracked by SignalX reported holding Journey Medical Corp (DERM) shares worth $10.8 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $61.2M
- +11.1% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 16 funds
- $10.8M · −2 vs prior quarter
- Latest 8-K
- Aug 12, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Quarterly revenue $18.5M, up 23% YoY from $15.0M
- Emrosi revenue $8.1M, up 189% YoY; Qbrexza lowest performer, down 26% to $5.1M
- Operating income $0.5M vs $2.9M loss YoY; operating margin 2.5% vs (19.2)%
- Cash $25.6M vs $24.1M at December 31, 2025; six-month operating cash flow $1.2M vs $(3.8)M
- Going-concern substantial doubt; potential debt or equity financing and generic competition cited as headwinds
Risk Factors
- No material changes disclosed from 2025 Form 10-K risk factors
- Additional unknown risks could materially adversely affect business, financial condition, or results
- No unregistered equity sales during the quarter
- No defaults upon senior securities reported
- No director or officer Rule 10b5-1 trading-plan activity during the quarter
AI summary of the DERM 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Journey Medical announced financial results for the three months ended June 30, 2026
- Corporate update and detailed results furnished in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q2 revenue $18.5M, up 23% year over year, led by Emrosi revenue of $8.1M
- Emrosi prescriptions reached approximately 36,000, up from 30,000 in Q1 2026 and 27,000 in Q4 2025
Item 5.07: Submission of Matters to a Vote of Security Holders
- 2026 annual meeting reached quorum with 81% representation, including 6 million super-voting Class A shares
- Six directors elected through 2027, with Neil Herskowitz receiving the highest withheld vote count at 1,381,937
Item 2.02: Results of Operations and Financial Condition
- Q1 2026 financial results and corporate update announced for quarter ended March 31, 2026
- Detailed results contained in Exhibit 99.1 press release
AI summaries of DERM 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for DERM
Don't miss the next DERM filing
- Alerts as it files. A push when DERM files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut DERM, by share count.
- Ask anything. An AI agent that reads every DERM filing and answers with sources.
DERM alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Toledano Miranda Jayne | A | Jun 25, 2026 | 10,000 | - |
| ROSENWALD LINDSAY A MD | A | Jun 25, 2026 | 10,000 | - |
| Pearce Michael Cooper | A | Jun 25, 2026 | 10,000 | - |
| Herskowitz Neil | A | Jun 25, 2026 | 10,000 | - |
| Smith Justin Adam | A | Jun 25, 2026 | 10,000 | - |
| Alloush Ramsey | A | Apr 22, 2026 | 46,863 | - |
| Maraoui Claude | A | Apr 22, 2026 | 82,915 | - |
| Alloush Ramsey | A | Apr 22, 2026 | 62,795 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $59.7M | $55.1M | $61.2M |
| Operating Income | -$2.1M | -$13.7M | -$8.2M |
| Net Income | - | -$14.7M | -$11.4M |
| Op. Margin | -3.5% | -24.8% | -13.3% |
| Net Margin | - | -26.6% | -18.7% |
| Balance Sheet | |||
| Total Assets | $76.8M | $80.2M | $94.6M |
| Equity | $20.4M | $20.1M | $31.9M |
| ROE | - | -73.1% | -35.9% |
| Per Share | |||
| EPS | $-0.21 | $-0.72 | $-0.47 |
| Cash Flow | |||
| Operating CF | $5.2M | -$9.1M | -$12.4M |
Source: XBRL data in Journey Medical Corp (DERM)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate DERM share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 16 | $10.8M |
| Q1 2026 | 18 | $15.9M |
| Q4 2025 | 18 | $20.8M |
| Q3 2025 | 15 | $13.7M |
| Q2 2025 | 12 | $11.9M |
| Q1 2025 | 9 | $4.4M |
| Q4 2024 | 6 | $2.6M |
| Q3 2024 | 3 | $1.8M |
- Morgan Stanley+31.5K (+299%)
- Goldman Sachs Group+20.9K (+30%)
- Bank of America Corp+9.7K (+30%)
- Citigroup+3.0K (+276%)
- PNC Financial Services+1.2K (+2993%)
- BlackRock−871.9K (-90%)
- Vanguard Capital Management LLC−406.9K (-38%)
- Millennium Management−273.1K (-71%)
- State Street Corp−171.3K (-72%)
- Northern Trust−114.3K (-76%)
- Citadel Advisors LLC+82.1K
- AQR Capital Management+24.9K
- Vanguard Portfolio Management LLC−122.2K
- BNY Mellon−37.2K
- T. Rowe Price Group−11.2K
- Wells Fargo & Co−7.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 97 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
DERM filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Aug 12, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 12, 2026 | - | Analysis | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 8-K | Jun 26, 2026 | - | Analysis | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 8-K | May 13, 2026 | - | Analysis | |
| 10-Q | May 13, 2026 | Mar 31, 2026 | Analysis | |
| SC 13G | Apr 30, 2026 | - | - | |
| 4 | Apr 24, 2026 | - | - | - |
| 4 | Apr 24, 2026 | - | - | - |
| 4 | Apr 24, 2026 | - | - | - |
| 8-K | Apr 21, 2026 | - | Analysis | - |
| 10-K | Mar 26, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 25, 2026 | - | - | - |
| 10-Q | Nov 12, 2025 | Sep 30, 2025 | Analysis | |
| 10-Q | Aug 12, 2025 | Jun 30, 2025 | - | |
| 10-Q | May 15, 2025 | Mar 31, 2025 | - | |
| SC 13G | May 13, 2025 | - | - | |
| 10-K | Mar 27, 2025 | Dec 31, 2024 | - | |
| SC 13G | Nov 29, 2024 | - | - | |
| 10-Q | Nov 12, 2024 | Sep 30, 2024 | - | |
| 10-Q | Aug 13, 2024 | Jun 30, 2024 | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
DERM SEC filings: frequently asked questions
Which institutions hold DERM stock?
As of June 30, 2026, the largest Journey Medical Corp (DERM) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($4.8 million), Renaissance Technologies LLC ($1.6 million), Millennium Management ($779,000), BlackRock ($716,000), Goldman Sachs Group ($639,000). 13F-HR reports are filed up to 45 days after each quarter ends.
What was DERM's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Journey Medical Corp (DERM) reported revenue of $61.2 million (up 11.1% from FY2024) and a net loss of $11.4 million. Diluted EPS was -$0.47. The figures come from the XBRL data in the 10-K.
What did DERM report in its latest 8-K?
Journey Medical Corp (DERM) filed an 8-K on August 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Journey Medical announced financial results for the three months ended June 30, 2026.
What are the latest DERM SEC filings?
Journey Medical Corp (DERM) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on August 12, 2026, an 8-K current report on August 12, 2026 and a Form 4 insider filing on June 29, 2026.
What is DERM's SEC CIK number?
Journey Medical Corp (DERM)'s SEC Central Index Key (CIK) is 1867066. EDGAR lists every DERM filing under that number.
Ask anything about DERM
The research agent reads DERM's filings, financials, insider trades and 13F holders, then answers with sources.